KMCRIC

Iron-chelating effect of silymarin in patients with β-thalassemia major: A crossover randomised control trial.

Darvishi-Khezri H, Salehifar E, Kosaryan M, Karami H, Mahdavi M, Alipour A, Aliasgharian A.

Phytother Res.

2017

Epub ahead of print

1-8.

10.1002/ptr.5995.

29235162

http://www.ncbi.nlm.nih.gov/pubmed/29235162

T2*-weighted magnetic resonance imaging (T2* MRI); iron chelating agents; iron overload; silymarin; transfusion dependent thalassemia; β-thalassemia major

T2*-weighted 자기 공명 영상; 철 킬레이트화 성분; 철분 과다; 실리마린; 수혈의존성 지중해성 빈혈; 베타 탈라세미아 메이저

없음

This study aimed to determine the potential iron-chelating effects of silymarin in patients with β-thalassemia major receiving standard iron-chelation therapy. We evaluated whether addition of silymarin to standard iron-chelation therapy could improve iron burden markers and liver and cardiac function in these patients, via a placebo-controlled, crossover clinical study. Silymarin (140 mg) or placebo were administered thrice daily to all patients (n = 82) for 12 weeks, and after a 2-week washout period, patients were crossed over to the other groups. Silymarin efficacy was assessed by measuring serum iron level, ferritin level, total iron-binding capacity and liver and cardiac function on magnetic resonance imaging. Silymarin treatment resulted in a negative change in the serum iron and ferritin levels and a positive change in the total iron-binding capacity levels (treatment effect, p < .001, p = .06, and p = .05, respectively). Silymarin treatment led to positive changes in cardiac and liver function in both treatment sequences of study; however, this was not statistically significant. There was a negative change in liver iron concentration in both treatment sequences (treatment effect, p = .02). In conclusion, combined iron-chelation and silymarin therapy was effective for improving the iron-burden status in patients with β-thalassemia major.

영어